DUS4L inhibitors constitute a chemical class designed to specifically antagonize the activity of the Dihydrouridine Synthase 4-Like (DUS4L) enzyme. DUS4L is an enzyme involved in the post-transcriptional modification of uridine residues to dihydrouridine in tRNA, which can influence the structure and function of tRNA molecules, thereby affecting protein synthesis. Inhibitors targeting this enzyme work by binding to the active site or other critical regions of DUS4L, thereby obstructing its ability to catalyze the reduction of uridine. The action of DUS4L inhibitors is not to be understood as merely obstructive but as a precise recalibration of the tRNA-related processes. By preventing the modification of uridine, these inhibitors can alter the structural dynamics of tRNA, potentially affecting its interaction with ribosomes and other elements of the translation apparatus. The consequence of this inhibition can result in a reduction of the translation fidelity or efficiency, which subsequently impacts protein production rates and can influence the cellular phenotype, especially in cells where rapid protein synthesis is crucial.
The biochemical specificity of DUS4L inhibitors is crucial to their functional impact. By selectively targeting the DUS4L enzyme, these inhibitors can exert a unique influence on the tRNA landscape within the cell. The specificity is found in the molecular structure of the inhibitors, which is designed to mimic or compete with the natural substrates of the enzyme or to bind to allosteric sites that induce conformational changes, thereby inactivating the enzyme's catalytic ability. This targeted approach allows for the modulation of the enzymatic activity of DUS4L without broadly affecting other RNA or DNA modifying enzymes. As a result, the translation process is influenced at a fundamental level, through the precise control over tRNA modification rather than through a blanket effect on protein synthesis. The inhibition of DUS4L, therefore, represents a fine-tuning mechanism by which cellular protein profiles can be subtly yet significantly altered, impacting the rate and composition of proteins being synthesized and thus the overall cellular function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of PI3K, which is upstream of AKT signaling. DUS4L inhibition can result from diminished AKT activity, as AKT can influence various downstream signaling cascades, including those related to cell growth and survival. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor that can lead to reduced AKT phosphorylation and activity. This reduction can indirectly decrease the activity of downstream proteins like DUS4L, which may be regulated by AKT-mediated pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can downregulate several downstream signaling pathways that are implicated in cell growth and proliferation, potentially reducing the activity of DUS4L if it is involved in these pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A MEK inhibitor, which by inhibiting the MEK/ERK pathway can decrease the activity of downstream proteins potentially including DUS4L, if it's implicated in cell cycle regulation or growth signal transduction. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Another MEK inhibitor that functions similarly to U0126, potentially leading to a decrease in DUS4L activity if it is involved in the MEK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor, which by inhibiting p38 MAPK can affect inflammatory responses and other signaling mechanisms that DUS4L might be a part of. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which plays a role in stress-induced apoptosis. Inhibition of JNK can lead to decreased DUS4L activity if DUS4L is part of apoptosis signaling pathways. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase inhibitor that can change the expression levels of various genes. If DUS4L expression is regulated by acetylation status, its activity may be indirectly decreased. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor that leads to hypomethylation of DNA and can alter gene expression. If DUS4L gene expression is epigenetically regulated, this could lead to its decreased activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can lead to the accumulation of misfolded proteins, potentially affecting the stability and function of DUS4L if it is susceptible to proteasomal degradation. | ||||||